Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients

Nephron - Clinical Practice

Volumn 97, Issue 1, 2004, Pages

  Almirall, Jaume ^a,d   Lopez, Thaïs ^a   Vallve, Montserrat ^a   Ruiz, Ana ^b   Llibre, Joan ^b   Betriu, Angels ^c  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b CETIRSA   (Spain)

^c Sistemes Renals   (Spain)

^d Hospital Universitari Parc Taulí   (Spain)

Author keywords

Cholesterol; Dialysis; Hyperphosphataemia; Phosphate binders; Sevelamer

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; HEADACHE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MALE; NAUSEA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RETROSTERNAL PAIN; VOMITING;

ADULT; AGED; CALCIUM; CHOLESTEROL; EPOXY COMPOUNDS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS;

EID: 2642512242     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077591     Document Type: Article

References (33)

1. Reiss E, Canterbury MJ, Bercovitz MA, et al: The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest 1970;49:2146-2149.
2. Slatopolsky E, Bricker NS: The role of phosphate restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 1973;4:141-145.
3. Lopez-Hilker S, Dusso A, Rapp N, et al: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990;259:F432-F437.
4. Delmez JA, Slatopolsky E: Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992;19:303-317.
5. Hsu CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-649.
6. Renaud H, Atik A, Hervé M, et al: Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: Lack of influence of calcium carbonate. Nephron 1988;48:28-32.
7. Lau K: Phosphate excess and progressive renal failure: The precipitation-calcification hypothesis. Kidney Int 1989;36:918-937.
8. Block GA, Hulbert-Shearon TE, Levin NW, et al: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-617.
9. Marchais SJ, Metivier F, Guérin AP, et al: Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999;14:2178-2183.
10. Guérin AP, London GM, Marchais SJ, et al: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
11. Goodman W, Goldin J, Kuizon B, et al: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
12. Slatopolsky E, Weerts C, Hilker SL, et al: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-161.
13. Fournier A, Morinière P, Sebert JL, et al: Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int Suppl 1986;18:S114-S119.
14. Andreoli SP, Dunson JW, Bergstein JM: Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987;9:206-210.
15. Mai ML, Emmett M, Sheikh MS, et al: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989;36:690-695.
16. Morinière P, Djerad M, Boudailliez B, et al: Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Nephron 1992;60:6-11.
17. Caravaca F, Santos I, Cubero JJ, et al: Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992;60:423-427.
18. Almirall J, Veciana L, Llibre J: Calcium acetate versus calcium carbonate for the control of serum phosphorus in haemodialysis patients. Am J Nephrol 1994;14:192-196.
19. Kaehny WD, Hegg AP, Alfrey AC: Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 1977;296:1389-1390.
20. Hodsman AB, Sherrard DJ, Alfrey AC, et al: Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab 1982;54:539-546.
21. Mactier RA, Van Stone J, Cox A, et al: Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Neprol 1987;28:222-226.
22. Andress DL, Norris KC, Coburn JW, et al: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-279.
23. Chertow GM, Burke SK, Lazarus JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
24. Wilkes BM, Reiner D, Kern M, et al: Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998;50:381-386.
25. Goldberg DI, Dillon MA, Slatopolsky EA, et al: Effect of RenaGel, a non-absorbed, calciumand aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998;13:2303-2310.
26. Chertow GM, Burke SK, Dillon MA, et al: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
27. Bleyer AJ, Burke SK, Dillon MA, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701.
28. Chertow GM, Dillon MA, Burke SK, et al: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999;51:18-26.
29. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299-307.
30. Braun J, Oldendorf M, Moshage W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
31. Arad Y, Spadaro LA, Goodman K, et al: Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36:1253-1260.
32. Burke SK, Slatopolsky EA, Goldberg DI: RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12:1640-1644.
33. Sadek T, Mazouz H, Bahloul H, et al: Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs. calcium carbonate in dialysis patients: An open-label, randomized study. Nephrol Dial Transplant 2003;18:582-589.